Claims
- 1. An expression vector comprising a recombinant vaccinia virus having a mutation in the region encoding the N-terminal position of the E3L gene product and further comprising exogenous DNA operably linked to regulatory elements that control expression thereof.
- 2. The expression vector of claim 1 having a deletion of the region encoding amino acids 1-83 of the E3L gene product.
- 3. The expression vector of claim 1 having a deletion of the region encoding amino acids 1-54 of the E3L gene product.
- 4. The expression vector of claim 1 wherein the region encoding the N-terminal portion of the E3L gene product encodes alanine at amino acid position 44 and leucine at amino acid position 66.
- 5. A composition comprising the vector of claim 1 and a carrier.
- 6. A composition comprising the vector of claim 2 and a carrier.
- 7. A composition comprising the vector of claim 3 and a carrier.
- 8. A composition comprising the vector of claim 4 and a carrier.
- 9. A method of making a recombinant gene product comprising subjecting an expression vector comprising a vaccinia virus having a mutation of the region encoding the N-terminal region of the E3L gene product and wherein said vector further comprises exogenous DNA that encodes said recombinant gene product operably linked to regulatory elements that control expression thereof, to conditions whereby said recombinant gene product is expressed.
- 10. The method of claim 9 further comprising recovering said recombinant gene product.
- 11. The method of claim 9 wherein said recombinant gene product is an antigen.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation-in-part of PCT/US00/10948 which application was published by the International Bureau in English on Dec. 7, 2001 and which claims priority of U.S. Application Serial No. 60/136,277. The disclosures of PCT/US00/10948 and 60/136,277 are incorporated herein by reference in their entireties.
STATEMENT REGARDING FEDERALLY FUNDED RESEARCH
[0002] Financial assistance for this project was provided by the U.S. Government through the National Institutes of Health under grant number CA-4865409 and the United States Government may own certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60136277 |
May 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US00/10948 |
Dec 2000 |
US |
Child |
09887295 |
Jun 2001 |
US |